CN102712672B - 用于治疗胆疾病的多羟基化胆汁酸 - Google Patents

用于治疗胆疾病的多羟基化胆汁酸 Download PDF

Info

Publication number
CN102712672B
CN102712672B CN201080048314.9A CN201080048314A CN102712672B CN 102712672 B CN102712672 B CN 102712672B CN 201080048314 A CN201080048314 A CN 201080048314A CN 102712672 B CN102712672 B CN 102712672B
Authority
CN
China
Prior art keywords
acid
tetrahydroxy
compound
bile
cholan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080048314.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102712672A (zh
Inventor
林重庆
王人学
杨神予
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingbaixinda Shanghai Pharmaceutical Technology Co ltd
Original Assignee
Chi Ching Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chi Ching Medicine Co Ltd filed Critical Chi Ching Medicine Co Ltd
Publication of CN102712672A publication Critical patent/CN102712672A/zh
Application granted granted Critical
Publication of CN102712672B publication Critical patent/CN102712672B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080048314.9A 2009-08-25 2010-08-25 用于治疗胆疾病的多羟基化胆汁酸 Active CN102712672B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23675009P 2009-08-25 2009-08-25
US61/236,750 2009-08-25
PCT/CA2010/001338 WO2011022838A1 (en) 2009-08-25 2010-08-25 Polyhydroxylated bile acids for treatment of biliary disorders

Publications (2)

Publication Number Publication Date
CN102712672A CN102712672A (zh) 2012-10-03
CN102712672B true CN102712672B (zh) 2016-09-14

Family

ID=43627124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080048314.9A Active CN102712672B (zh) 2009-08-25 2010-08-25 用于治疗胆疾病的多羟基化胆汁酸

Country Status (7)

Country Link
EP (1) EP2470553B1 (https=)
JP (1) JP5909774B2 (https=)
CN (1) CN102712672B (https=)
AU (1) AU2010286253A1 (https=)
BR (1) BR112012004284B8 (https=)
SG (1) SG178562A1 (https=)
WO (1) WO2011022838A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013041519A1 (en) 2011-09-19 2013-03-28 ETH Zürich, ETH Transfer Ror gamma modulators
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
SG11201503697TA (en) * 2012-11-28 2015-06-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
JP6556129B2 (ja) * 2013-08-01 2019-08-07 アメリカ合衆国 ファルネソイドｘ受容体の阻害剤及び医薬としての使用
CN104523703A (zh) * 2014-12-24 2015-04-22 聂飚 一种游离脂肪酸转运蛋白小分子抑制物的应用
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
EP3890745B1 (en) 2018-12-04 2025-11-19 President and Fellows of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
KR102204406B1 (ko) * 2019-01-23 2021-01-18 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물
CN109762043B (zh) * 2019-03-06 2020-07-24 华南理工大学 鹅去氧胆酸及其制备方法
KR20250171471A (ko) 2019-05-10 2025-12-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 장 박테리아 담즙산 대사의 소분자 조정제
CN116925168A (zh) * 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
CN110548037B (zh) * 2019-09-24 2023-06-02 江西天元药业有限公司 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途
CN113024624B (zh) * 2019-12-25 2024-09-10 上海科胜药物研发有限公司 一种去氧胆酸的合成方法
WO2022233398A1 (en) 2021-05-04 2022-11-10 Kostner Pharma Gmbh COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
CN115337312B (zh) * 2022-08-19 2025-06-03 金熊药业(珠海横琴)有限公司 胆酸复合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116814A1 (en) * 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition and uses thereof
WO2006116815A1 (en) * 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition for the control of cholesterol levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
RU2224523C2 (ru) * 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
US20110263546A1 (en) * 2008-02-26 2011-10-27 Renxue Wang Polyhydroxylated Bile Acids for Treatment of Biliary Disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116814A1 (en) * 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition and uses thereof
WO2006116815A1 (en) * 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition for the control of cholesterol levels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Preparation of glycine-conjugated bile acids and theis gas/liquid chromatographic analysis on an aluminum-clad flexible used silica capillary column;Takashi lida等;《BIOMEDICAL CHROMATOGRAPHY》;19921231;第6卷;4-8 *
Synthesis of 3α,6β,7α,12β-and3α,6β,7β,12β-tetrahydroxy-5β-cholanoic acids;Suresht K等;《Steroids》;19920531;第57卷;107-111 *

Also Published As

Publication number Publication date
WO2011022838A1 (en) 2011-03-03
EP2470553B1 (en) 2024-06-19
JP5909774B2 (ja) 2016-04-27
EP2470553A1 (en) 2012-07-04
BR112012004284B1 (pt) 2021-01-05
EP2470553A4 (en) 2013-02-20
JP2013502442A (ja) 2013-01-24
BR112012004284A2 (pt) 2017-06-13
EP2470553C0 (en) 2024-06-19
CN102712672A (zh) 2012-10-03
WO2011022838A8 (en) 2011-06-16
AU2010286253A1 (en) 2012-04-19
BR112012004284B8 (pt) 2021-05-25
SG178562A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
CN102712672B (zh) 用于治疗胆疾病的多羟基化胆汁酸
US10543220B2 (en) Polyhydroxylated bile acids for treatment of biliary disorders
CA2716922C (en) Polyhydroxylated bile acids for treatment of biliary disorders
Weerachayaphorn et al. Nuclear factor-E2-related factor 2 is a major determinant of bile acid homeostasis in the liver and intestine
Meng et al. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis
ES2858355T3 (es) Composiciones que comprenden aminoácidos para su uso en la prevención y el tratamiento de enfermedades hepáticas
Soden et al. Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis
Abed et al. The protective effect of metformin against oxandrolone-induced infertility in male rats
EP2392337B1 (en) Use of 24-norUDCA
HK1176622B (en) Polyhydroxylated bile acids for treatment of biliary disorders
HK1176622A (en) Polyhydroxylated bile acids for treatment of biliary disorders
Millet et al. Partial inhibition of proteasome activity enhances remyelination after cuprizone-induced demyelination
US20220227804A1 (en) Combination of a polyhydroxylated bile acid and a farnesoid x receptor agonist
Golonka Sex, Aging, and Gut Microbiota on Bile Acid Metabolism in Liver Cancer
Ceci Melatonin-MT1 Signaling Axis Ameliorates the Phenotypes of Primary Sclerosing Cholangitis
Truong Roles for Bile Transporters in the Pathogenesis and Treatment of Liver and Intestinal Diseases
Coy Physiological and toxicological roles of ABC transporters in cellular efflux of substrates
DK059630 ABLATING L-FABP IN SCP-2/SCP-X NULL MICE IMPAIRS BILE ACID METABOLISM AND BILIARY 2 HDL-CHOLESTEROL SECRETION 3
Verkade et al. Articles in PresS. Am J Physiol Gastrointest Liver Physiol (November 8, 2012). doi: 10.1152/ajpgi. 00322.2012
Hagey et al. Nuclear factor-E2-related factor 2 is a major determinant of bile acid 2 homeostasis in the liver and intestine 3
DE ROISSART Functional role of the ductular reaction in the maintenance of the hepatobiliary bile flow
HK1161122B (en) Use of 24-norudca
HK1161121B (en) 24-norudca for treating autoimmune hepatitis
HK1161121A (en) 24-norudca for treating autoimmune hepatitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1176622

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160324

Address after: British Columbia

Applicant after: Danqing Pharmaceutical Co.,Ltd.

Address before: British Columbia

Applicant before: Lin Zhongqing

Applicant before: Wang Renxue

Applicant before: Yang Shenyu

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1176622

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20200820

Address after: No. 205.207, south of building 17, industrialization base of small and medium sized enterprises in bio pharmaceutical Park, 1777 Dazheng Road, hi tech Zone, Jinan City, Shandong Province

Patentee after: Shandong Qingbai Xinda Pharmaceutical Technology Co.,Ltd.

Address before: British Columbia

Patentee before: Danqing Pharmaceutical Co.,Ltd.

TR01 Transfer of patent right
CP03 Change of name, title or address

Address after: 201318 floor 1-2, building 2, Lane 500, Furonghua Road, Pudong New Area, Shanghai

Patentee after: Qingbaixinda (Shanghai) Pharmaceutical Technology Co.,Ltd.

Country or region after: China

Address before: 250101 No.1777 Dazheng Road, High-tech Zone, Jinan City, Shandong Province, Biopharmaceutical Park, Small and Medium-sized Enterprise Industrialization Base, Building 17, South side, Room 205 and 207

Patentee before: Shandong Qingbai Xinda Pharmaceutical Technology Co.,Ltd.

Country or region before: China

CP03 Change of name, title or address